Novartis Makes Mayzent Case With More MS Data

 
• By Kevin Grogan

Presentations at ECTRIMS highlight the recently approved pill's effects on disability and cognition.  

Wheelchair
Mayzent can help patients keep their mobility for over four years longer • Source: Shutterstock

More from Neurological

More from Therapy Areas